Osteopontin: a potential biomarker for successful bee venom immunotherapy and a potential molecule for inhibiting IgE-mediated allergic responses.

Venom immunotherapy (VIT) is proven to be curative for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. We report herein the discovery of a leading candidate biomarker, osteopontin (OPN), for VIT. From cDNA microarray and clustering analyses, an increased expression of OPN was found in patients who completed 5-6 years of VIT and discontinued therapy for 3-6 years as compared with the untreated group. A significantly higher level of serum OPN was found in the completed treatment group as compared with the untreated group. Following VIT, kinetically increased levels of OPN associated with reduced venom specific IgE levels were noted in subjects with large local allergic reactions to venom. These findings together with the fact that OPN is involved in Th1-associated immune response strongly suggest a role of OPN as a functional biomarker for VIT.

[1]  J. Schroeder,et al.  Level of osteopontin is increased after bee venom immunotherapy. , 2005, The Journal of allergy and clinical immunology.

[2]  Shau-ku Huang,et al.  Endotoxin contamination contributes to the in vitro cytokine-inducing activity of osteopontin preparations. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[3]  J. Schroeder,et al.  Increased expression of osteopontin is associated with long-term bee venom immunotherapy. , 2005, The Journal of allergy and clinical immunology.

[4]  P. Kuo,et al.  The role of Osteopontin in tumor metastasis. , 2004, The Journal of surgical research.

[5]  L. Liaw,et al.  Altered bleomycin-induced lung fibrosis in osteopontin-deficient mice. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[6]  S. Kikuchi,et al.  Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients , 2003, Journal of Neuroimmunology.

[7]  Y. Saeki,et al.  Enhanced local production of osteopontin in rheumatoid joints. , 2002, The Journal of rheumatology.

[8]  M. Noda,et al.  Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  K. Sullivan,et al.  An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus , 2002, Human mutation.

[10]  Jorge R. Oksenberg,et al.  The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease , 2001, Science.

[11]  A. Kagey‐Sobotka,et al.  Case report of venom immunotherapy for a patient with large local reactions. , 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  K. Sullivan,et al.  Cytokine and chemokine dysregulation in hyper-IgE syndrome. , 2001, Clinical immunology.

[13]  M. Noda,et al.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. , 2001, The Journal of clinical investigation.

[14]  A. O’Regan,et al.  Osteopontin: a key cytokine in cell‐mediated and granulomatous inflammation , 2000, International journal of experimental pathology.

[15]  G. Nau,et al.  Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. , 2000, Immunology today.

[16]  D. Golden.  STINGING INSECT VACCINES , 2000, Radiologic Clinics of North America.

[17]  D. Golden.  Stinging insect vaccines: patient selection and administration of Hymenoptera venom immunotherapy. , 2000 .

[18]  M. Glimcher,et al.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. , 2000, Science.

[19]  R. Young,et al.  Attenuated Host Resistance againstMycobacterium bovis BCG Infection in Mice Lacking Osteopontin , 1999, Infection and Immunity.

[20]  S. Spector,et al.  STINGING INSECT HYPERSENSITIVITY: A PRACTICE PARAMETER ☆ ☆☆ ★ ★★ , 1999 .

[21]  D. Denhardt,et al.  Osteopontin Function in Pathology: Lessons from Osteopontin-Deficient Mice , 1999, Nephron Experimental Nephrology.

[22]  G. Chupp,et al.  Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. , 1999, Journal of immunology.

[23]  C. Akdis,et al.  Role of interleukin 10 in specific immunotherapy. , 1998, The Journal of clinical investigation.

[24]  D. Golden,et al.  Discontinuing venom immunotherapy: extended observations. , 1998, The Journal of allergy and clinical immunology.

[25]  M. Murakami,et al.  Osteopontin, a Coordinator of Host Defense System: a Cytokine or an Extracellular Adhesive Protein? , 1997, Microbiology and immunology.

[26]  A. Enk,et al.  Insect venom immunotherapy induces interleukin‐10 production and a Th2‐to‐Th1 shift, and changes surface marker expression in venom‐allergic subjects , 1997, European journal of immunology.

[27]  J. Bousquet,et al.  Asthma, nasal allergies, and multiple sclerosis. , 1997, The Journal of allergy and clinical immunology.

[28]  M. Lorber,et al.  Allergy and SLE: common and variable. , 1997, Israel journal of medical sciences.

[29]  L. Steinman,et al.  Regulation of disease susceptibility: decreased prevalence of IgE-mediated allergic disease in patients with multiple sclerosis. , 1996, The Journal of allergy and clinical immunology.

[30]  D. Golden,et al.  Discontinuing venom immunotherapy: outcome after five years. , 1996, The Journal of allergy and clinical immunology.

[31]  P. Lachmann,et al.  A comparative study of IgG subclass antibodies in patients allergic to wasp or bee venom , 1994, Allergy.

[32]  R. H. Hamilton,et al.  Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. , 1992, The Journal of allergy and clinical immunology.

[33]  S. Durham.  Mechanisms of immunotherapy. , 2008, Drugs of today.

[34]  谷野 洋子.  Sequence variants of the SPP1 gene are associated with total serum IgE levels in a Japanese population , 2006 .

[35]  M. Noda,et al.  Osteopontin expression and function: Role in bone remodeling , 1998, Journal of cellular biochemistry. Supplement.